Session Chair Profile

M.D., Ph.D., President, Eisai Center for Genetics Guided Dementia Discovery (G2D2), Eisai Inc.

Nadeem is the Founder and President of the Eisai Center for Genetics Guided Dementia Discovery (G2D2) – an autonomous “spin-in” biotech exclusively focused on harnessing human genetics, data sciences, and precision chemistry. G2D2 is located at a new, tailored-designed 50,000 Sqft facility in Cambridge, MA. Nadeem sits on the US National Academies of Science, Engineering and Medicine’s Roundtable on Genomics & Precision Health (within which he co-leads the Precision Therapeutics working group), and has served as Chair - US Institute of Medicine Workshop on “Drug Discovery From Genetic Bioresources”; Chair - World CNS Summit; Chair - Festival of Genomics; Chair - External Advisory Board, NIA Longevity Genomics Study; Industry Lead - ADNI Genetics; and Scientific Board, IMI-EPAD. Before joining Eisai, Nadeem was Senior Director, Head of Population Research & Head of Cardiometabolic Genetics, at Pfizer Inc. Prior to working in the pharmaceutical industry, Nadeem was tenured faculty at the School of Clinical Medicine, University of Cambridge (UK).

 Session Abstract – PMWC 2020 Silicon Valley

Track 3, January 22

The vast majority of available genomic data is from participants that are of white, European ancestry, therefore representing a fraction of the world’s population only. Continued disproportionate advances in genome sciences will exacerbate global healthcare disparities in several ways. This session will address how coordinated, multi-sector solutions could address and preempt such disparities to ensure the promise of precision medicines is realized globally.